

-1600

Express Mail No. EV 019561603 UR
Attorney Docket TAR.06

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: LI ET AL.

SERIAL NO.: 09/976,254

FILED:

OCTOBER 11, 2001

TITLE:

TARGETED THERAPEUTIC AGENTS

EXAMINER:

ART UNIT:

CONFIRMATION NO.:

RECEIVED

JUN 1 3 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies enclosed, which may be material to examination of the above identified application.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed under 37 CFR § 1.97(b). This Statement is filed within at least one of the following time periods:

- (a) within three months of the filing date of a national application (other than a CPA under 37 CFR § 1.53(d));
- (b) within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application;
- (c) before the mailing of a first Office Action of the merits; or
- (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114.

No fee is believed to be due in this instance. However, the undersigned hereby authorizes the charging of any fees created by the filing of this document to Deposit Account No. 19-5117.

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,

Darla G. Yoerg, #48,053/ Swanson & Bratschun, L.L.C. 1745 Shea Center Drive, Suite 330

Highlands Ranch, Colorado 80129

(303) 268-0066

Karen Brunke cc:

S:\CLIENT FOLDERS\TARGESOME\06\UTILITY\IDS.DOC